BioMed Partners and HTGF lead €10.7m round for Tubulis

Also participating in the round were Seventure Partners, Coparion, Bayern Kapital and Occident, as well as a number of high-net-worth individuals and Tubulis's founders.

The company plans to use the funding to progress its first two ADC candidates to clinical trials.

Switzerland-headquartered BioMed focuses on early-stage and mid-stage life sciences companies, investing up to CHF 10m per platform investment, generally acting as lead or co-lead investor in syndications.

Coparion generally participates in funding rounds of €1-5m, investing up to €10m per company, while Occident writes tickets from €500,000, investing from seed rounds onwards and focusing on "deep tech" startups.

Company
Founded in 2019 as a spin-out from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin (FMP) and the Ludwig Maximilians University (LMU) in Munich, Tubulis develops antibody-drug conjugates (ADC) which have potential for use in cancer treatment.

Dominik Schumacher, Christian Hackenberger, Heinrich Leonhardt and Jonas Helma-Smets are co-founders and have conducted the research on which the company's medical technology is based. Headquartered in Munich, the company has five employees.

People
Tubulis – Dominik Schumacher (co-founder, CEO).
BioMed Partners – Michael Wacker (partner).
High-Tech Gründerfonds – Lena Krzyzak (senior investment manager).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Germany
• High-Tech Gründerfonds